Telmisartan‐enhanced hypercholesterolaemic serum‐induced vascular endothelial growth factor expression in immortalized human umbilical vascular endothelial cells

Abstract

Objective. To clarify whether hypercholesterolaemia can increase vascular endothelial growth factor (VEGF) expression in human umbilical vascular endothelial cells (HUVECs) through the phosphatidylinositol 3‐kinase (PI3K) pathway, and whether a special angiotensin II receptor blocker, telmisartan, can attenuate VEGF expression induced by hypercholesterolaemia. Methods. Levels of VEGF expression, PI3K activity and angiogenesis in vitro were determined by various methods after HUVECs were incubated with hypercholesterolaemic serum or combined with telmisartan and/or wortmannin. Results. We found that hypercholesterolaemic serum (cholesterol ⩾0.08 mmol/L) can increase VEGF expression in HUVECs and that telmisartan cooperates with hypercholesterolaemic serum in promoting VEGF expression. The increased VEGF expression was associated with enhanced PI3K activity and could be significantly inhibited by wortmannin, a potent PI3K inhibitor. Likewise, hypercholesterolaemic serum significantly promoted angiogenesis in vitro, which could be inhibited when PI3K activity was suppressed. Conclusions. Our study suggests that hypercholesterolaemic serum induces VEGF expression through PI3K in HUVECs and that telmisartan cooperates with hypercholesterolaemia in promoting VEGF expression.

• Endothelium
• hypercholesterolaemia
• PI3‐kinase
• telmisartan
• VEGF

Acknowledgements

This work was supported by a grant from the Science and Technology Bureau of Zhejiang Province (021110240). We thank the entire laboratory for fruitful discussions.